Bone Affecting Patents (Class 514/16.7)
-
Publication number: 20140072574Abstract: A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.Type: ApplicationFiled: September 10, 2013Publication date: March 13, 2014Applicant: National Tsing Hua UniversityInventors: Margaret Dah-Tsyr Chang, Lin-Shien Fu, Shun-Lung Fang
-
Publication number: 20140057843Abstract: This invention relates to a plurality of compositions for dietary health management and its use in the prevention or treatment of any one of the disease states in the group consisting of cardiovascular disease, inflammation and diarrhoea. Human evolution has been a very slow process in contrast to the relatively recent, rapid changes in our diet since the Neolithic revolution which marked the switch from hunter-gatherer to agricultural life-style around 10,000 years ago. Moreover our genome has not had time to evolve at the same pace and therefore it is postulated that our bodies will work more efficiently with an ancestral diet.Type: ApplicationFiled: May 25, 2011Publication date: February 27, 2014Inventors: Mark John Berry, Heather Frances Jennifer Bligh, John Casey, Karl John Hunter, Rober Antoine Kemperman
-
Publication number: 20140056855Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.Type: ApplicationFiled: January 19, 2012Publication date: February 27, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Kit S. Lam, Ruiwu Liu, Wei Yao, Nancy Lane
-
Publication number: 20140057833Abstract: Short peptide mimetics of adiponectin suitable for development as pharmaceutical agonists in the treatment of cellular proliferative disorders such as cancer and atherosclerosis are provided.Type: ApplicationFiled: April 11, 2012Publication date: February 27, 2014Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Laszlo Otvos, Eva Surmacz
-
Publication number: 20140056960Abstract: The invention provides a method of promoting bone formation in a patient at a site in need thereof, the method comprising the step of locally administering a pro-inflammatory compound to the site, wherein the pro-inflammatory compound is selected from one or more of TNF-? at optimal osteogenic dose of 0.5 to 50 ng/kg of patient body weight, or 0.01 to 3.5 ?g, or 1 ng/ml or similar; IL-1? at optimal osteogenic dose of 0.1 ng/ml or similar; alarmins eg HMGB1, HMGN1, S100A8, S100A9, S100A8/9, S100A12, heat shock proteins, lactoferrin, cathelicidins, a-defensins, matrix components including versican, biglycan, fragments of hyaluronic acid and heparan sulphate; and TLR-2 or TLR-4 ligands. The invention also provides the above pro-inflammatory compounds for use in promoting bone formation in a patient at a site in need thereof. Kits comprising the compounds of the invention and a surgical implant are also provided.Type: ApplicationFiled: December 29, 2011Publication date: February 27, 2014Applicant: Imperial Innovations LimitedInventors: Jagdeep Nanchahal, Nicole Horwood
-
Publication number: 20140050739Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: ApplicationFiled: October 11, 2013Publication date: February 20, 2014Applicant: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 8653029Abstract: The present invention provides a composition that may be used as an implant or a bone graft substitute or extender for filling voids and/or promoting fusion of osseous tissues. The implant may comprise ceramic granules such as calcium phosphate granules and one or more polysaccharide excipients, and may be in the form of a putty or flowable paste. Optionally, the implant may also comprise a growth factor such as a bone morphogenetic protein.Type: GrantFiled: July 30, 2009Date of Patent: February 18, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Scott Mitchell Vickers, Jeffrey L. Scifert
-
Publication number: 20140045760Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: ApplicationFiled: October 17, 2013Publication date: February 13, 2014Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Fred HOFMANN, Jurgen Frevert
-
Publication number: 20140045756Abstract: The present disclosure relates to methods and compositions for modulating TNF and TNFR signaling. In particular, the disclosure describes methods and compositions for inhibiting TNF? signaling, such as in the prevention or treatment of TNF?-related diseases.Type: ApplicationFiled: March 9, 2012Publication date: February 13, 2014Applicant: New York UniversityInventor: Chuan-Ju Liu
-
Publication number: 20140037634Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.Type: ApplicationFiled: May 24, 2013Publication date: February 6, 2014Inventors: Randolph J. Noelle, Li Wang
-
Publication number: 20140037594Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone formation (e.g., osteoporosis).Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Applicant: NORTHWESTERN UNIVERSITYInventor: Ming Zhang
-
Patent number: 8642728Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.Type: GrantFiled: October 6, 2009Date of Patent: February 4, 2014Assignee: Cambridge Enterprise Ltd.Inventors: John Trowsdale, Alexander Barrow, Richard Farndale
-
Publication number: 20140018286Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: ApplicationFiled: September 26, 2013Publication date: January 16, 2014Applicant: NOVO NORDISK A/SInventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
-
Patent number: 8629109Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.Type: GrantFiled: July 5, 2011Date of Patent: January 14, 2014Assignee: Acceleron Pharma Inc.Inventors: John Knopf, Jasbir Seehra
-
Publication number: 20140011730Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.Type: ApplicationFiled: September 12, 2013Publication date: January 9, 2014Applicant: Ipsen Pharma S.A.S.Inventors: Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
-
Patent number: 8623825Abstract: Disclosed is describes a method of increasing bone strength and/or increasing bone resistance to bending and/or improving bone architecture and/or maintaining bone status in a human, comprising administering to said human a composition comprising a fat source, wherein said fat source is a triglyceride fat source comprising triglycerides with 15-55% palmitic acid moieties out of the total fatty acids, and wherein the level of palmitic acid moieties at the sn-2 position of the glycerol backbone is at least 30% (w/w) of total palmitic acid. Said method is particularly intended for subjects at risk of impaired bone strength. Further disclosed is said fat source, as well as food articles and a commercial package comprising the same.Type: GrantFiled: July 31, 2008Date of Patent: January 7, 2014Assignee: Enzymotec Ltd.Inventors: Fabiana Bar-Yoseph, Dori Pelled, Yael Lifshitz
-
Patent number: 8617585Abstract: An intramedullary drug delivery device is disclosed and can be inserted within a bone canal of a bone. The intramedullary drug delivery device can include a housing. A drug delivery region can be established along the housing. Also, the drug delivery region can be configured to substantially span a fracture within the bone.Type: GrantFiled: March 23, 2006Date of Patent: December 31, 2013Assignee: Warsaw Orthopedic, Inc.Inventors: Scott D. Boden, Jeffrey L. Scifert, James S. Marotta
-
Patent number: 8618045Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.Type: GrantFiled: December 21, 2011Date of Patent: December 31, 2013Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Patent number: 8614190Abstract: Thermal responsive compositions for treating bone diseases are provided. The thermal responsive composition for treating bone diseases includes a bone growth factor and a biodegradable copolymer. The biodegradable copolymer has a structure of Formula (I) or Formula (II): A-B-BOX-B-A??Formula (I) B-A-B-(BOX-B-A-B)n-BOX-B-A-B??Formula (II) wherein, A includes a hydrophilic polyethylene glycol polymer, B includes a hydrophobic polyester polymer, BOX is a bifunctional group monomer of 2, 2?-Bis(2-oxazoline) and used for coupling the blocks A-B or B-A-B, and n is an integer and the same or more than 0.Type: GrantFiled: June 29, 2011Date of Patent: December 24, 2013Assignee: Industrial Technology Research InstituteInventors: Shen-Hua Peng, Hsin-Hsin Shen, Liang-Yo Yang, Meng-Yow Hsieh, Pei-Shan Li, Wei-Lin Yu, Tsai-Yu Lin, Po-Liang Lai, Jui-Sheng Sun, Chih-Hung Chang, Yi-Hung Lin
-
Patent number: 8614189Abstract: The present invention provides biocompatible composite materials that can be fabricated into a scaffold having properties suitable for bone repair and regeneration. These scaffolds have sufficient mechanical strength to be useful for the repair and regeneration of cortical bone.Type: GrantFiled: September 21, 2009Date of Patent: December 24, 2013Assignee: University of ConnecticutInventors: Cato T. Laurencin, Syam Prasad Nukavarapu, Sangamesh G. Kumbar
-
Publication number: 20130337028Abstract: The present invention relates to synthetic peptides for use in bone tissue repair and regeneration applications. The present invention also relates to various compositions and devices (including implantable orthopedic/dental devices) that contain the synthetic peptides of the present invention, and methods involving the use of the synthetic peptides of the present invention. The present invention also relates to a bone replacement or bone-reconstructive material, which includes a polymer matrix and a synthetic peptide of the present invention.Type: ApplicationFiled: June 22, 2011Publication date: December 19, 2013Applicant: NANOVIS, INC.Inventors: Ganesan Balasundaram, Matthew Hedrick
-
Patent number: 8609616Abstract: A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).Type: GrantFiled: July 14, 2011Date of Patent: December 17, 2013Assignee: Osteologix A/SInventors: Christian Hansen, Henrik Nilsson, Stephan Christgau, Henry G Bone, III
-
Publication number: 20130331310Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.Type: ApplicationFiled: December 10, 2012Publication date: December 12, 2013Inventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8603981Abstract: A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment.Type: GrantFiled: November 22, 2002Date of Patent: December 10, 2013Assignee: Protista Biotechnology ABInventors: Tadeusz Studzinski, Jose Luis Valverde Piedra, Stefan Pierzynowski
-
Patent number: 8598121Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).Type: GrantFiled: May 8, 2012Date of Patent: December 3, 2013Assignee: Biomarin Pharmaceutical Inc.Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
-
Publication number: 20130309214Abstract: A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle.Type: ApplicationFiled: September 29, 2011Publication date: November 21, 2013Applicant: SIRIM BERHADInventors: Fazilah Binti Fazan, Salina Sabudin, Shirin Binti Ibrahim, Sudirman Bin Sahid, Wan Ruzaini Bin Wan Sulaiman, Nor Shahida Binti Kader Bashah
-
Publication number: 20130302357Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Patent number: 8580740Abstract: A milk protein fraction having following properties (1) to (4) is excellent in bone resorption inhibitory effect, and is useful for preventing or treating bone diseases: (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein having a molecular weight of 12,000 to 16,000 Daltons; (3) the milk protein fraction has a basic amino acid content of 18 to 20 wt % in the constitutional amino acid composition, and the ratio of the amount of a basic amino acid(s) to the amount of an acidic amino acid(s) is 0.7 to 0.9; and (4) the milk protein fraction has a bone resorption inhibitory effect.Type: GrantFiled: October 28, 2008Date of Patent: November 12, 2013Assignee: Megmilk Snow Brand Co., Ltd.Inventors: Atsushi Serizawa, Yoshikazu Morita, Daisuke Uetsuji, Aiko Ono, Hiroaki Matsuyama, Satoshi Higurashi
-
Patent number: 8575101Abstract: Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, which are used to heal bone fractures, particularly bone fractures with a risk of becoming delayed unions or non-unions, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction with the matrix and/or the granules. These supplemented matrices decrease the time of healing compared to autograft and or trigger healing of bone fractures which otherwise would not heal. The matrices are biocompatible, preferably biodegradable, and can be formed in vitro or in vivo, at the time of implantation. The PTH may be a part of a fusion peptide. PTH can be incorporated into the matrices with full retention of its bioactivity. PTH can be releasably incorporated in the matrix.Type: GrantFiled: June 23, 2011Date of Patent: November 5, 2013Assignee: Kuros Biosurgery AGInventors: Jason Schense, John Watson, Isabelle Arrighi
-
Patent number: 8575098Abstract: The present invention relates to a biopolymer, bioactive and totally biocompatible, very fluid at ambient temperature, capable of gelling in a sudden manner at 37° C., forming a solid implant, structurally integral and continuous having high mechanical properties. The biopolymer comprises at least a bioactive domain capable of directing in a precise manner the formation of a solid or semisolid implant. Furthermore the invention relates to any of the nucleic acids encoding the amino acid sequence of the biopolymer, implants, pharmaceutically acceptable vehicles, uses thereof, and a method of synthesis thereof.Type: GrantFiled: February 16, 2010Date of Patent: November 5, 2013Assignee: Universidad de ValladolidInventors: José Carlos RodrÃguez Cabello, Matilde Alonso Rodrigo, Francisco Javier Arias Vallejo, Alessandra Girotti, Laura MartÃn Maroto, Ana MarÃa Testera Gorgojo
-
Publication number: 20130287765Abstract: The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.Type: ApplicationFiled: April 12, 2013Publication date: October 31, 2013Applicants: University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount SinaiInventors: Mone Zaidi, Harry C. Blair
-
Publication number: 20130287817Abstract: A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials.Type: ApplicationFiled: April 27, 2012Publication date: October 31, 2013Applicant: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Daniel A. Shimko
-
Publication number: 20130281356Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventors: Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin
-
Patent number: 8563513Abstract: Provided herein are Parathyroid hormone (PTH) peptides and parathyroid hormone-related protein (PTHrP) peptides (e.g., PTH analogs, PTHrP analogs), and related variants, chemical derivatives, fusion polypeptides, multimeric polypeptides, and peptidomimetics, peptoids, the like. Also provided are their use in methods for activating the PTH receptor in a cell (e.g., an osteoblast), methods of treating a subject with bone loss (e.g., by administration of a PTH peptide or PTHrP peptide (e.g., a PTH analog or PTHrP analog)), methods of ameliorating a symptom associated with osteoporosis in a subject, methods of retarding the progression of osteoporosis in a subject, and methods of regenerating bone in a subject.Type: GrantFiled: March 26, 2010Date of Patent: October 22, 2013Assignees: Van Andel Research Institute, The General Hospital CorporationInventors: Huaqiang Eric Xu, Augen A. Pioszak, Thomas J. Gardella
-
Publication number: 20130267463Abstract: Provided are a pharmaceutical use of poly-gamma-glutamic acid used for preventing or treating Th17-mediated diseases, a composition for preventing or treating Th17-mediated diseases comprising poly-gamma-glutamic acid as an active ingredient, and a method of preventing or treating Th17-mediated diseases using the same. The pharmaceutical composition is effective in inhibiting the differentiation of Th17 cells while promoting Treg cells, and, thus, can be useful in preventing or treating Th17-mediated diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, and the like.Type: ApplicationFiled: November 15, 2012Publication date: October 10, 2013Applicant: Industry-University Cooperation Foundation Hanyang UniversityInventors: Jeehee YOUN, Tae-Hwan KIM, Kyuheon LEE
-
Patent number: 8546529Abstract: The present invention relates to an injectable bone regeneration material containing a bone formation enhancing peptide, and more particularly, to an injectable bone regeneration material, in which a bone formation enhancing peptide essentially containing one and more amino acid sequences among SEQ ID NO: 1 to SEQ ID NO: 28 is bonded or mixed to a gel-forming base material selected from the group consisting of chitosan, alginic acid, silk fibroin, propylene glycol, propylene glycol alginic acid, poloxamer, chondroitin sulphate, and the combination thereof. The injectable bone regeneration material according to the present invention can increase differentiation of bone marrow stromal cells and osteoblasts into bone tissue, thus maximizing tissue regeneration by a peptide capable of promoting differentiation of bone tissue and periodontal tissue regeneration. The injectable bone regeneration material is in the form of a gel, and thus can be applied to a surface of various medical devices such as implant etc.Type: GrantFiled: June 5, 2008Date of Patent: October 1, 2013Assignees: Nano Intelligent Biomedical Engineering Corporation Co., Ltd., Seoul National University Industry FoundationInventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee
-
Patent number: 8545927Abstract: The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As described herein, cross-linked lactoferrin biomatrix retains the bioactivities of the lactoferrin molecule. The biomatrix composition can act as a matrix for cell adhesion and growth and is particularly useful in musculoskeletal tissue regeneration. The biomatrix compositions can be pre-formed or injectable and can act as a cell, drug or protein delivery vehicle.Type: GrantFiled: May 10, 2011Date of Patent: October 1, 2013Assignee: University of ConnecticutInventor: Lakshmi Sreedharan Nair
-
Patent number: 8546334Abstract: The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.Type: GrantFiled: March 27, 2002Date of Patent: October 1, 2013Assignee: Scil Technology GmbHInventors: Ulrich Kohnert, Sylke Pohling, Klaus Hellerbrand, Peter Happersberger
-
Patent number: 8545888Abstract: The invention relates to tendon stem cell useful for treating a variety of diseases and conditions, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation by use of biglycan and/or fibromodulin.Type: GrantFiled: June 13, 2008Date of Patent: October 1, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Marian F. Young, Yanming Bi, Songtao Shi
-
Publication number: 20130251762Abstract: Described herein are novel methods of producing collagen-apatite (Col-Ap) scaffolds that exhibit a unique, anisotropic multi-level lamellar structure in which nano and submicron pores in each lamellae and macro pores are co-aligned.Type: ApplicationFiled: March 22, 2013Publication date: September 26, 2013Applicant: THE UNIVERSITY OF CONNECTICUTInventors: Mei Wei, Zengmin Xia
-
Publication number: 20130251689Abstract: A bone graft composition is described, with one or more of: (a) keratose; (b) kerateine; (c) optionally, particulate filler; (d) optionally, an antibiotic; and (e) water or saline. The composition may be provided in sterile form in a container, and optionally lyophilized. Methods of treating a bone deficiency or fracture making use of such compositions are also described.Type: ApplicationFiled: May 16, 2013Publication date: September 26, 2013Applicant: Wake Forest University Health SciencesInventors: Mark E. Van Dyke, Thaleia Teli
-
Publication number: 20130244942Abstract: The invention features fiber reinforced bone repair putties and fiber reinforced pliable lyophilized implants which are useful for the treatment of bone defects. The putties and lyophilized implants include ceramic particles. The formulations of the invention can exhibit reduced migration of the ceramic particles, and are mechanically strengthened so the materials can be aggressively manipulated by a physician during an implantation procedure without tearing or puncturing.Type: ApplicationFiled: December 21, 2012Publication date: September 19, 2013Applicant: Cerapedics, Inc.Inventors: James J. BENEDICT, Nolan Chase Hannigan, Katherine Suzanne Davis, Whitney Terese Young
-
Patent number: 8536128Abstract: The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or the molecules they interact with, for instance COMP, in cartilage disorders, including arthritis. Assays and screening methods for the determination of the expression and activity of GEP, or of GEP-COMP, are provided, including for screening for the presence or extent of cartilage or arthritic disease and for identifying modulators or compounds/agents for treatment or prevention of cartilage or arthritic diseases.Type: GrantFiled: March 8, 2011Date of Patent: September 17, 2013Assignee: New York UniversityInventors: Chuanju Liu, Sally Frenkel
-
Publication number: 20130237484Abstract: The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.Type: ApplicationFiled: April 25, 2011Publication date: September 12, 2013Applicants: Nanao Intelligent Biomedical Engineering Corporation Co., Ltd., Seoul National University R&DB FoundationInventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, Jin Sook Suh
-
Publication number: 20130237472Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof.Type: ApplicationFiled: September 7, 2011Publication date: September 12, 2013Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Publication number: 20130230520Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.Type: ApplicationFiled: April 24, 2013Publication date: September 5, 2013Applicant: Kyowa Hakko Kirin Co., LtdInventors: Makoto KAKITANI, Kazuma TOMIZUKA
-
Publication number: 20130230573Abstract: A method of fabricating a collagen structure, is disclosed. The method comprises applying onto a surface in a layerwise manner acidic solutions of liquid crystalline collagen and a crosslinker to form a layered structure. The acidic solutions that correspond to at least two adjacent layers have different concentrations of the crosslinker therein.Type: ApplicationFiled: November 16, 2011Publication date: September 5, 2013Inventors: Oded Shoseyov, Amit Yaari
-
Patent number: 8524662Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.Type: GrantFiled: December 28, 2010Date of Patent: September 3, 2013Assignee: DePuy Mitek, LLCInventors: Ben Byers, Dongling Su, Julia Hwang
-
Publication number: 20130225484Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: AMGENInventor: AMGEN
-
Publication number: 20130216504Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.Type: ApplicationFiled: December 21, 2012Publication date: August 22, 2013Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCEInventor: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE